Another disappointing result for Alzheimer Drug Lilly has announced another failure of a late stage clinical trial. Please paste this link if you are interested: https://www.businessweek.com/ap/2012-08-24/lilly-alzheimers-drug-trial-yields-promising-sign
There is not much left of late stage or even newer trials for Alzheimer's disease.
Meanwhile Bellus has not issued any information regarding NRM8499. They also previously stated that they would not be issuning any updates for Kiacta. Well that lack of information and policy certainly had devastating effect on the price of the stock. It has been completely obliterated. This more than likely will result in an additional huge dilution of the company's shares. I guess it is ok if you are on the receiving end of stock options or renumeration.
This is not a good situation.